COPENHAGEN, Denmark, April 24, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced upcoming presentations related to its rare disease endocrinology pipeline.
Four poster presentations will take place at the upcoming conferences listed below, including two presentations related to the TransCon hGH (human growth hormone) phase 3 program in pediatric growth hormone deficiency and two related to the TransCon PTH (parathyroid hormone) program in hypoparathyroidism.
“These presentations highlight additional analyses from the TransCon hGH phase 3 heiGHt Trial supporting the top-line results, and the design of our ongoing TransCon PTH phase 2 PaTH Forward trial, including new data about the economic burden caused by hypoparathyroidism,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO. “These posters reflect our strong commitment to patients and science.”
Details about the presentations are listed below. Following the sessions, poster presentations will be available on the company’s website under Selected Publications in the Pipeline section.
Pediatric Endocrinology Nursing Society (PENS): TransCon hGH
|TransCon hGH as a Long-Acting Growth Hormone for the Treatment of Pediatric Growth Hormone Deficiency ||Friday, April 26 |
5:45 p.m. – 7:15 p.m. (Pacific time)
Pediatric Endocrine Society (PES): TransCon hGH
|The Pivotal Phase 3 heiGHt Trial of Weekly TransCon hGH vs. Daily hGH in Treatment-Naïve Subjects with Pediatric Growth Hormone Deficiency||Saturday, April 27 |
1:15 p.m. – 2:30 p.m. (Eastern time)
European Calcified Tissue Society (ECTS): TransCon PTH
|The Design of a Long-acting PTH (TransCon PTH) Phase 2 Trial in Patients with Hypoparathyroidism, based on Phase 1 Results in Healthy Subjects ||Sunday, May 12 |
10:10 - 10:30 (Central European summer time/CEST)
Monday, May 13
12:00 - 13:00 (CEST)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR): TransCon PTH
|Impacts of Hypoparathyroidism on Patient Work Productivity and Out-of-Pocket Costs||Monday, May 20 |
3:30 – 7:00 p.m.
About TransCon™ Technology
TransCon is short for “transient conjugation.” The proprietary TransCon platform is an innovative technology to create new therapies that optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technology can be applied broadly to a protein, peptide or small molecule, and is applicable in multiple therapeutic areas.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three independent rare disease endocrinology product candidates in clinical development and has established oncology as its second therapeutic area of focus. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology and continues to expand into additional therapeutic areas for both internal and external development.
Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.
For more information, please visit www.ascendispharma.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create potentially best-in-class therapies and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2018, which we filed with the SEC on April 3, 2019. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.© April 2019 Ascendis Pharma A/S.
Scott T. Smith
Chief Financial Officer
Head of Global Communications